AU9134191A - Use of certain glutarimide derivatives in the treatment of depression and mania - Google Patents

Use of certain glutarimide derivatives in the treatment of depression and mania

Info

Publication number
AU9134191A
AU9134191A AU91341/91A AU9134191A AU9134191A AU 9134191 A AU9134191 A AU 9134191A AU 91341/91 A AU91341/91 A AU 91341/91A AU 9134191 A AU9134191 A AU 9134191A AU 9134191 A AU9134191 A AU 9134191A
Authority
AU
Australia
Prior art keywords
alkyl
azaspiro
dione
decane
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU91341/91A
Inventor
Maurice W. Gittos
Marcel Hibert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of AU9134191A publication Critical patent/AU9134191A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Description

USE OF CERTAIN GLUTARIMIDE DERIVATIVES IN THE TREATMENT OF
DEPRESSION AND MANIA
This invention relates to the manufacture of certain glutarimide derivatives for their use as medicaments in the treatment of depression and mania.
More specifically, this invention relates to the use in the manufacture of a medicament for treating depression and mania utilizing a compound of the formula
their geometric, stereo- or optical isomers, the mixtures thereof, and the pharmaceuticallyacceptableacid addition salts thereof, wherein X is selected from the group consisting of
Rχ is hydrogen, C1_4 alkyl, C1_4 alkoxy, halogeno, nitro, hydroxy, S03H, S02NK2, or S02NH2-CH2-,
R2 is hydrogen, C1_4 -alkyl, Cχ_4 alkoxy, halogeno, nitro or hydroxy, and
R and R2, taken together with the carbon atoms to which they are attached, form a benzenoid moiety at the indicated 1,2- or 3,4-positions,R3 is H or C1_4 alkyl,
R_ and R5 are H, C1-4 alkyl or, when taken together with the carbon atom to which they are attached, form a C3_6 cycloalkyl moiety, n is an integer of 2 to 5 inclusive, A and B independently are oxygen, sulfur or NR3, their geometric, stereo- or optical isomers and the mixtures thereof, and the pharmaceutically acceptable acid addition salts thereof.
As used herein the term "pharmaceutically acceptable acid addition salts" is intended to apply to any non-toxic organic or inorganic acid addition salts of the base compounds represented by Formula (1). Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulphuric and phosphoric acid and acid metal salts such as sodium πtonohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids which form suitable salts include the mono-, di- and tricarboxylic acids. Illustrative of such acids are for example, acetic, glycolic, lactic, pyruvic, alonic, succinic, glutaric, fu aric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, p-hydroxybenzoic, phenylacetic, cinnamic, salicylic, 2-phenoxybenzoic acids, and sulfonic acids such as methanesulfonic acid or 2-hydroxyethane- sulfonic acid. Either the mono- or the di-acid salts can be formed, and such salts can exist in either a hydrated or a substantially anhydrous form. In general, the acid addition salts of these compounds are crystalline materials which are soluble in water and in various hydrophilic organic solvents. Additionally, in comparison to their free base forms, such salts generally demonstrate higher melting points and an increased chemical stability.
As used herein, C1_/. alkyl includes the straight and branched alkyl radicals having 1 to 4 carbon atoms such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl and the like. C1_4 alkoxy includes the straight and branched alkoxy radicals such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, isobutoxy and the like. Halogeno includes chloro, bro o and fluoro. The isomers contemplated include the position isomers, the stereoisomers as well as the enantiomeric isomers, and the mixtures thereof. The individual isomers of the compounds of formula I may best be prepared by processes designed to enrich the production of the desired isomers. However, mixtures may be resolved or isolated according to conventional and standard procedures well known in the art, e.g. chromatographic separation, fractional crystallization, use of optically active acids, enzymatic resolution and the like.
In essence, the compounds of formula (1) contain a glutarimide moiety joined to the defined X moieties by a
(CH2)π alkylene bridging moiety. Preferably n represents 2 o
5. Illustrative of the X moieties are:
(2,3-dihydro-l, -benzodioxin-2-yl)methylamino,
(2,3-dihydro-l,4-benzoxathiin-3-yl)methylamino, (2,3-dihydro-l,4-benzodithiin-2-yl)methylamino, (2,3-dihydro-l,4-benzoxazin-3-yl)methylamino, (2,3-dihydro-l,4-dihydroquinazolin-2-yl)methylamino, (2,3-dihydronaphtho[1,2-b] [1,4]dioxin-2-yl)methylamino, (2,3-dihydronaphtho[1,2-b] [1,4]dioxin-3-yl)methylamino, (indol-3-yl)ethylamino,
(1,2,3,4-tetrahydro-β-carbolinyl) , and tetralin-2-amino and the Rχ, R2 and/or R3 substituted analogs.
Specific subclasses of compounds that fall within the the present invention are illustrated as follows:
8-[ω-[ (2,3-dihydro-l,4-benzodioxin-2-yl)methylamino]alkyl]' 8-azaspiro[4,5ldecane-7,9-diones,
(1a)
8-[ω-[ (2,3-dihydro-l,4-benzoxathiin-3-yl)methylamino]alkyi; 8-azaspiro[4,5]decane-7,9-diones,
(1b)
g-[ω-[ (2,3-dihydro-l,4-benzodithiin-2-yl)methylamino]alkyl] 8-azasoiro[4,5]decane-7,9-diones,
(1c)
8-[ω-[ (2,3-dihydro-l,4-benzoxazin-3-yl)methylamino]alkyl]-8- azaspiro [4,5] decane-7 , 9-diones ,
(1d)
8-[ω-[ (2,3-dihydroquinazolin-2-yl)methylamino]alkyl]-8- azaspiro[4,5]decane-7,9-diones,
de)
8-[ω-[ (2,3-dihydronaphtho[l,2-b] [1,4]dioxin-2- yl)methylamino]-alkyl]-8-azaspiro[4,5]decane-7,9-diones
Of)
(Compounds of this sub-class can be substituted either at the 2- or 3-position of the dioxin ring.) 8-[ω-[ (indol-3-yl)ethylamino]alkyl]-8-azaspiro[4, 5]decane- 7,9-diones,
dg)
8-[ω-[l,2,3,4-tetrahydro-β-carbolinyl]alkyl]-8- azaspiro[ 4,5]-decane-7 ,9-diones,
(1h)
8-[ω-[ (substituted)tetralin-2-amino]alkyl]-8-azaspiro[ 4,5]■ decane-7,9-diones,
di) Of course, in each of the illustrative structures (1a) to (1i), the compounds are depicted without the Rχ, R2 and R3 substitutents (other than H) , but it is understood that the illustrative structures include those compounds bearing the defined Rχ, R2 and/or R3 substituents.
For convenience, the glutarimide moiety has been depicted as an 8-azaspiro[4,5]decane-7,9-dione but also included are the corresponding 4,4-dimethyl-2,6- piperidinedione derivatives. Obviously, also, the β-carbolinyl moiety of formula (1h) can also be named as [4- (l,2,3,4-tetrahydro-9H-pyrido[3,4-b]-indol-2-yl] .
A preferred subclass of this invention consists of .those compounds of formula (1h) wherein the X moiety is an
R1-substituted-l,2,3,4-tetrahydro-β-carboline ring system.
Another preferred subclass of this invention relates to those compounds of formula (1f) wherein the X-moiety is a 2,3 dihydronaphtho[l,2-] [l,4]-dioxin-2-yl or 3-yl ring system.
Another preferred class of compounds of this invention relates to those compounds of formula (1a) wherein the X-moiety is terminally substituted by the 2,3-dihydro-l,4- benzodioxin-2-yl ring system.
The aromatic glutarimide derivatives of formula (1) can be prepared via a condensation of theappropriate nucleophilic a ine of formula (2) with an appropriate glutarimide substrate of formula (3) using processes and techniques analogously known in the art, such as that shown by the following reaction scheme.
(2) (3) (1) wherein X, R4, R5 and n are as defined in formula (1) and the symbol (L) represents a suitable leaving group, such as chlorine, bromine, iodine, a mesylate, tosylate or hydroxyl.
Such a nucleophilic condensation is preferably conducted by reacting approximately equimolar amounts of the nucleophile (2) with the substrate (3), for a period of from about 1 hour to 24 hours depending upon the particular reactants employed. The reaction temperature can range from about 25°C to 150°C. Preferably the reaction is conducted at a temperature ranging from 60°Cto 150°C. Further details and specific exemplification for the nucleophilic condensation have been previously described in U.S. Patent 4,612,312, issued on September 16, 1986.
The nucleophilic primary amines indicated by formula (2) are compounds which are either commercially available or which have been previouslydescribed in the literature. Generic teachings and the details and exemplifications for the preparation of the nucleophilic primary amines embraced by Formula (2) of this invention may readily be obtained from issued U.S. Patent 4,612,312 and U.S. Patent 4,748,182 issued May 31, 1988.
The compounds of formula (3) are essentially N-alkyl derivatives of glutarimide. The leaving groups (L) for compounds of formula (3) can represent any group known to those skilled in the art, such as a tosylate (OTS) or a mesylate (OMS), an iodide, bromide or chloride, or hydroxyl group. Generic teachings and the details and exemplifications for the preparation of the glutarimide reactants of Formula (3) (and the precursors therefor) are readily obtained from issued U.S. Patent 4,612,312.
Illustrative of the preferred compounds of this invention are:
8-[4-(l,4-benzodioxan-2-ylmethylamino)butyl]-8-azaspiro- [4,5] ecane-7,9-dione;
8-[4-(1,4-benzodioxan-2-ylmethyl-N-methylaιrtino)butyl]-8- azaspiro[4,5]decane-7,9-dione, hydrochloride salt;
8-[4-(1,4-benzodioxan-2-ylmethyl-N-ethylamino)butyl]-8- azaspiro[4,5]decane-7,9-dione, oxalate, 0.5 H20;
8-[4-(1,4-benzodioxan-2-ylmethyl-N-n-propylamino)butyl]-8- azaspirof4,5]decane-7,9-dione, oxalate;
8-[4-(l,4-benzodio>:ar.-2-ylmethyl-N-isopropylamino)butyl]-8- azaspiro[4,5]decane-7,9-dione, oxalate;
8-[4-(1,4-benzoxazine-2-ylmethylamino)butyl]-8-azaspiro- [4,5] ecane-7, -dione;
N-[4-(1,4-benzodioxan-2-ylmethylamino)butyl]-3,3-dimethyl- glutarimide, hydrochloride;
(-)8-[4-(l,4-benzodioxan-2-ylmethylamino)butyl]-8-azaspiro- [4,5]άecane-7,9-dione; 8-[2-(1,4-benzodioxan-2-ylmethylamino)ethyl]-8-azaspiro- [4,5]-decane-7,9-dione;
8-[2-(l,4-benzodioxan-2-ylmethylamino)ethyl]-8-azaspiro- [4,5]-decane-7,9-dione;
8-[5-(1,4-benzodioxan-2-ylmethylamino)n-pentyl]-8-azaspiro- [4,5]decane-7 ,9-dione;
8-[4-(2,3-dihydronaphtho[l,2,b]dioxin-2- ylmethylamino)butyl]-8-azaspiro[4,5]decane-7,9-dione;
8-[4-(2,3-dihydronaphtho[1,2,b]dio in-2-ylmethyl- amino)butyl]-8-azaspiro[4,5]decane-7,9-dione;
8-[4-(5,6-dimethy1-1,4-benzodioxan-2-yl)methyl(n- methylamino)-butyl]-8-azaspiro[4,5]decane-7,9-dione;
8-[3-(5,7-di-n-butyl-l,4-benzodioxan-2-yl)methyl(n-n-propyl- amino)propyl]-8-azaspiro[4,5]decane-7,9-dione;
9-[2-(5,8-dihydroxy-l,4-benzodioxan-2-yl)methyl(n- ethylamino)-ethyl]-9-azaspiro[5,5]undecane-8,10-dione;
9-[2-(5,8-dimethoxy-l,4-benzodioxan-2-yl)methyl(n-2-hydroxy- ethylamino)ethyl]-9-azaspiro[5,5]undecane-8,10-dione;
9-[2-(5,8-di-n-butoxy-l,4-benzodioxan-2-y1)methyl(n-2- hydroxyethylamino)ethyl]-9-azaspi o[5,5]undecane-8,10-dione;
8-[2-(5-chloro-l,4-benzodioxan-2-yl)methyl(n- ethylamino)ethyl]-8-azaspiro[4,5]decane-7,9-dione;
8-[2-(5-fluoro-1,4-benzodioxan-2-yl-methylamino)ethyl]-8- azaspiro[4,5]decane-7,9-dione; 8-[2-(5-nitro-1,4-benzodioxan-2-y1-methylamino)ethyl]-8- azaspiro[4,5] ecane-7,9-dione; 8-[2-(5-aminosulfonyl-1,4-benzodioxan-2-yl- methylamino)ethyl]-8-azaspiro[4,5]decane-7,9-dione;
8-[2-(5-sulfo-l,4-benzodioxan-2-y1-methylamino)ethyl]-8- azaspiro[4,5]decane-7,9-dione;
8-[4-[ (1,2,3 ,4-tetrahydro-8-methoxy-2-naphthalenyl)amino]- butyl]-8-azaspiro[4,5]decane-7,9-dione, hydrochloride;
8-[4-(l,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-2-yl)butyl]- 8-azaspiro[4,5]decane-7,9-dione, hydrochloride;
,4-άimethyl-l-[4-(1,2,3,4-tetrahydro-9E-pyrido-[3,4- b]indol-2-yl)butyl]-2,6-piperidinedione, hydrochloride;
6-methoxy-8-[4-(1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indol-2- yl)-butyl]-8-azaspiro[4,5]decane-7,9-dione, hydrochlo ide;
8-[4-[ (3,4-dihydro-2H-l,4-benzoxazin-3- yl)methylamino]butyl]-8-azaspiro[4,5]decane-7,9-dione, oxalate;
8-[5-[2-(5-methoxy-3-indolyl)ethylamino]butyl]-8- azaspiro[4,5]-decane-7,9-dione, oxalate;
3-dihydro-5-methoxy-l,4-benzodioxin-2-yl)ethyl]-8-azaspiro- [4,5]decane-7,9-dione, hydrochloride;
8-[2-[(2,3-dihydro-8-methoxy-l,4-benzodioxin-2-yl)ethyl]-8- azaspiro[4,5]decane-7,9-dione, hydrochloride;
8-[4[ (1 ,4-benzodioxin-2-yl)methylamino]butyl]-8-azaspiro- [4,5]decane-7,9-dione, hydrochloride; 2-[4-[ (2,3-dihydro-l,4-benzodioxin-2-yl)methylamino]butyl]- lH-isoindole-l,3(2H)-dione, methanesulfonate (salt), hemihydrate; 8-[4-[ (2,3-dihydro-5-methoxy-l,4-benzodioxin-2-yl)methyl]- butyl]-8-azaspiro[4,5]decane-7,9-dione, monohydrochloride;
2-[4-[ (2,3-dihydro-8-methoxy-l,4-benzodioxin-2-yl)methyl]- butyl]-lH-isoindole-l,3(2H)-dione, monohydrochloride;
8-[4-[ (2,3-dihydro-8-methoxy-l,4-benzodio in-2-yl)methyl]- butyl]-8-azaspiro[4,5]decane-7,9-dione, ethanedioate salt.
U.S. Patent 4,612,312 teaches that certain compounds of this invention have properties which are useful for the treatment of hypertension and for treating anxiety. It recently has been found that the compounds possess properties which also will render them useful in the treatment of affective disorders, i.e., the compounds will be useful in the pharmacological treatment of depression and mania.
In general, the compounds of the prior art which have been found to be successful in the treatment of affective disorders have also been characterized as "mood elevators" and in recent years a plethora of the tricyclic-type of compounds have been found to be mood elevators having anti- depressant effects in endogenous and involutional depression. Illustrative of such successful tricyclic compounds are amitriphyline, desipramine, imipramine, nortriptyline, opipranol, depepin and butriptyline. Of course, many other tricyclic compounds are known but listing all such compounds is unnecessary here as they may be readily ascertained from standard works well known in the art. It is to the end-use application of these compounds to which the compounds of this invention will be useful.
Based upon standard laboratory assays as well as by comparison with compounds known to be useful in treating depression and mania, it is to be found that the compounds of this invention are effective 5HT1A agonists capable of exerting a pharmacological effect useful for the treatment of depression and mania in the general range of 0.005 to 10 mg/kg of patient body weight, but preferably in the range of 0.05 to 5 mg/kg of patient body weight per day.
The compounds of this invention can be administered either orally, subcutaneously, intravenously, intramuscularly, intraperitoneally or rectally. The preferred route of administration is oral. The amount of compound to be administered can be any effective amount, and will vary depending upon the patient, the mode of administration and the severity of the anxiety to be treated. Repetitive daily administration of the compounds may be desirable, and will vary depending upon the patient's condition and the mode of administration.
For oral administration, an anti-depressant effective amount of a formula (1) compound can range from 0.005 to 10 mg/kg of patient body weight per day, preferably from 0.05 to 5 mg/kg of patient body weight per day. The preferred dose of the compounds of formula (1) is about 0.1 mg/kg of patient body weight per day. Pharmaceutical compositions in unit dose form can contain from 1 to 50 mg of active ingredient and can be taken one or more times per day.
For parenteral administration, an anti-depressant effective amount of a formula (1) compound can range from 0.005 to 10 mg/kg of patient body weight per day, preferably from 0.05 to 5 mg/kg of patient body weight per day. A parenteral composition in unit dose form can contain from 0.1 g to 10 mg of active ingredient and can be taken one or more times daily.
For oral administration the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, melts, powders, solutions, suspensions or emulsions. Solid dosage unit forms generally employed include capsules or tablets. Capsules can be of the ordinary gelatin type which contain additional excipients such as surfactants, lubricants and inert fillers such as lactose, sucrose and cornstarch. Additionally, the compounds of formula (1) can be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders, such as acacia, cornstarch or gelatin, disintegrating agents such as potato starch or alginic acid, and lubricants such as stearic acid or magnesium stearate.
For parenteral administration the compounds may be administered as injectable dosages of a solution or a suspension of the compound in a physiologically acceptable diluent with or without a pharmaceutical carrier. Suitable diluents or carriers include sterile liquids such as water or oils, with or without the addition of surfactants or other pharmaceutically acceptable adjuvants. Illustrative of various oils that can be employed in the practice of this invention are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, and mineral oil. In gneral, water, saline, aqueous dextrose and related sugar solutions, ethanol and glycols such as propylene glycol or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions.

Claims (10)

WHAT IS CLAIMED IS:
1. A process for treating affective disorders which comprises administering to a patient in need thereof a therapeutically amount of a compound of the formula
their geometric, stereo- or optical isomers, the mixtures thereof, and the pharmaceuticallyacceptableacid addition sales thereof, wherein X is selected from the group consisting of
_χ is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogeno, nitro, hydroxy, S03H, S02NK2, or S02NH2-CH2- R2 is hydrogen, C1_. alkyl, C1-4 alkoxy, halogeno, nitro or hydroxy, and Rχ and R2, taken together with the carbon atoms to which they are attached, form a benzenoid moiety at the indicated 1,2- or 3,4-positions, R3 is H or C1-4 alkyl, R4 and R5 are H, C1-4 alkyl or, when taken together with the carbon atom to which they are attached, form a C3_6 cycloalkyl moiety, n is an integer of 2 to 5 inclusive,
A and B independently are oxygen, sulfur or NR3.
2. A process according to Claim 1 wherein X is a moiety having the structure
R4 and R5, together with the carbon atom to which they are attached, form a cyclopentyl moiety.
3. A process according to Claim 1 wherein the compounds are 8-[2-(2,3-dihydro-l,4-benzodioxin-2-ylmethylamino) ethyl]-8-azaspiro[4,5]decane-7,9-dione,methylsulfonate and 8-[4-[ (2,3-dihydronaphtho[l,2-b]-l,4-dioxin-2-yl)methyl- amino]butyl]-8-azaspiro[4,5]decane-7,9-dione,hydrochloride.
4. A process according to Claim 3 wherein the affective disorder is depression.
5. A process according to Claim 3 wherein the affective disorder is mania. METHOD-OF-USE CLAIMS
6. The use in the manufacture of a medicament for the treatment of depression and mania of compounds of the formula
their geometric, stereo- or optical isomers, the mixtures thereof, and the pharmaceuticallyacceptable acid addition salts thereof, wherein X is selected from the group consisting of
\γ is hydrogen, C1-4 alkyl, C1-4 alkoxy, halogeno, nitro, hydroxy, S03H, S02NH2, or S02NH2-CH2- R2 is hydrogen, C1_4 alkyl, C1-4 alkoxy, halogeno, nitro or hydroxy, and Rχ and R2, taken together with the carbon atoms to which they are attached, form a benzenoid moiety at the indicated 1,2- or 3,4-positions, R3 is H or C1-4 alkyl, R4 and R5 are H, Cλ_. alkyl or, when taken together with the carbon atom to which they are attached, form a C3_6 cycloalkyl moiety, n is an integer of 2 to 5 inclusive,
A and B independently are oxygen, sulfur or NR3.
7. The use in the manufacture of a medicament wherein X is a moiety having the structure
R4 and R5, together with the carbon atom to which they are attached, form a cyclopentyl moiety.
8. The use in the manufacture of a medicament according to claim 6 wherein the compounds are 8-[2-(2,3-dihydro-l,4- benzodioxin-2-ylmethylamino)ethyl]-8-azaspiro[4,5]decane-
7,9-dione,methylsulfonate and 8-[4-[ (2,3-dihydronaphtho[1,2- b]-l,4-dioxin-2-yl)methylamino]butyl]-8-azaspiro[4,5]decane- 7,9-dione,hydrochloride.
9. The use in the manufacture according to Claim 8 wherein the affective disorder is depression.
10. The use in the manufacture of a medicament according to claim 6 wherein the affective disorder is mania.
AU91341/91A 1990-12-24 1991-12-02 Use of certain glutarimide derivatives in the treatment of depression and mania Abandoned AU9134191A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90403757 1990-12-24
EP90403757 1990-12-24

Publications (1)

Publication Number Publication Date
AU9134191A true AU9134191A (en) 1992-07-22

Family

ID=8205790

Family Applications (1)

Application Number Title Priority Date Filing Date
AU91341/91A Abandoned AU9134191A (en) 1990-12-24 1991-12-02 Use of certain glutarimide derivatives in the treatment of depression and mania

Country Status (7)

Country Link
EP (1) EP0564520A1 (en)
JP (1) JPH06504279A (en)
KR (1) KR930702976A (en)
AU (1) AU9134191A (en)
CA (1) CA2097607A1 (en)
HU (1) HU9301856D0 (en)
WO (1) WO1992011011A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2552929C1 (en) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Pharmaceutical composition, containing derivatives of glutarimides, and their application for treatment of eosinophilic diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361565A (en) * 1981-12-28 1982-11-30 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyridines
CA1244418A (en) * 1984-07-30 1988-11-08 Marcel Hibert Glutarimide antianxiety and antihypertensive agents
DE3680123D1 (en) * 1985-01-23 1991-08-14 Glaxo Group Ltd Tetrahydrocarbazolonderivate.
US4748182A (en) * 1986-03-05 1988-05-31 Merrell Dow Pharmaceuticals Inc. Aromatic 2-aminoalkyl-1,2-benzoisothiazol-3(2H)one-1,1-dioxide derivatives and their use as anti-hypertensive and anxiolytic agents
US4788290A (en) * 1987-12-11 1988-11-29 American Home Products Corporation Serotonergic pyrazine derivatives
DE3831888A1 (en) * 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg MEDICINES FOR TREATING APOPLEXIA CEREBRI
EP0375819A1 (en) * 1988-12-20 1990-07-04 Merrell Dow Pharmaceuticals Inc. Novel derivatives of 1,7'-[imidazo-[1,2-a]pyridine]5'-(6'H)ones

Also Published As

Publication number Publication date
HU9301856D0 (en) 1993-09-28
WO1992011011A1 (en) 1992-07-09
CA2097607A1 (en) 1992-06-24
EP0564520A1 (en) 1993-10-13
JPH06504279A (en) 1994-05-19
KR930702976A (en) 1993-11-29

Similar Documents

Publication Publication Date Title
ES2286491T3 (en) PIPERIDINA-FTALAZONAS REPLACED WITH PIRROLIDINADIONA, AS INHIBITING AGENTS OF THE PDE4.
KR970009588B1 (en) Heterocyclic compounds
JP4995076B2 (en) GSK-3 inhibitor
JP5484726B2 (en) GSK-3 inhibitor
US20120035185A1 (en) Method of Using Flibanserin for Neuroprotection
JPH0517457A (en) Benzisothiazole and benzisoxazole piperazine derivative
FR2792938A1 (en) NOVELS 1-AMINO TRIAZOLO [4.3-a] QUINAZOLINE-5-ONES INHIBITORS OF IV PHOSPHODIESTERASES
EP2760450A1 (en) Monoacylglycerol lipase inhibitors for the treatment of metabolic diseases and related disorders
JPH03115283A (en) Novel 5, 11-dihydro-6h-dipyride(3, 2-b:2', 3'-e) (1, 4)diazepine-6-one and-thione and aids prophylactic or therapeutical agent containing said compound
JP6527513B2 (en) Quinazoline derivatives as TAM family kinase inhibitors
US20080045510A1 (en) Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
JP3117725B2 (en) Kainic acid neurotoxicity inhibitors and pyridothiazine derivatives
HUT74691A (en) N-substituted azabicycloalkane derivatives, their preparation and use
AU9134191A (en) Use of certain glutarimide derivatives in the treatment of depression and mania
JP3199736B2 (en) Aminoalkyl-substituted 2-amino-5-mercaptothiadiazole, production and use thereof
JP2021127289A (en) Condensed pyrimidine derivative
US20030114463A1 (en) Tetrahydroindolone and purine derivatives linked to arylpiperazines
EP0492021A1 (en) Use of certain 1,2-benzoisothiazol-3(2H)-1,1-dioxide derivatives in the treatment of depression and mania
JP2004043456A (en) Medicine containing benzazepine derivative or its salt as active component
JP2799892B2 (en) New derivatives
HU208077B (en) Process for producting pharmaceutical compositions against vomiting and nausea, comprising ergoline derivatives
HU204821B (en) Process for producing endo-n-braces open brackets open (8-methyl-8-azabicyclo/3,2,1/octan-3/yl)-amino brackets closed -carbonyl braces closed-2-(cyclopropylmethoxy)-benzamide, its salts and pharmaceutical compositions comprising such compounds as active ingredient
HU189562B (en) Process for production of n-allil-5-chlor-n/4,5-dihydro-1/1-imidazol-2-il/-2,1-3-benzotiadiazol-4-amin
Degardin et al. N-substituted bis-C-alkyloxadiazolones as dual effectors: Efficient intermediates to amidoximes or amidines and prodrug candidates of potent antimalarials
KR100226328B1 (en) 4-(4- or 6-(trifluoromethyl-2-pyridinyl))-1-piperazinylalkyl substituted lactams